Want to see KYMR full AI Analyst Report?
KYMR Stock Chart & Stats
$110.57
-$0.08(-0.07%)
At close: 4:00 PM EDT
$110.57
-$0.08(-0.07%)
Day’s Range― - ―
52-Week Range$39.84 - $130.05
Previous CloseN/A
Volume157.52K
Average Volume (3M)1.05M
Market Cap
$9.96B
Enterprise Value$10.65K
Total Cash (Recent Filing)$690.99M
Total Debt (Recent Filing)$82.22M
Price to Earnings (P/E)―
Beta1.80
Next Earnings
Oct 29, 2026EPS Estimate
-1.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.25
Shares Outstanding83,150,620
10 Day Avg. Volume575,796
30 Day Avg. Volume1,051,347
Financial Highlights & Ratios
PEG Ratio-0.89
Price to Book (P/B)4.16
Price to Sales (P/S)167.51
P/FCF Ratio-28.02
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$131.33Price Target Upside18.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
EPS Forecast (FY)-3.81
Revenue Forecast (FY)$106.15M
Bulls Say, Bears Say
Bulls Say
Cash RunwayThe sizable liquidity position gives Kymera time to fund multiple clinical programs and absorb development setbacks without immediate financing pressure, supporting sustained investment in its targeted protein degradation platform.
Accelerated Clinical ExecutionFaster enrollment brings pivotal efficacy data and potential Phase III initiation forward, improving development efficiency and enabling earlier validation of KT-621’s commercial potential in inflammatory disease.
Partnered Pipeline ValidationProgress under Sanofi and Gilead collaborations provides external validation of Kymera’s degrader platform, diversifies development support, and creates potential milestone and royalty opportunities beyond internally funded programs.
Bears Say
Persistent Losses And Cash BurnKymera has not demonstrated operating leverage and continues to consume substantial cash while funding research and trials. Persistent losses increase dependence on existing liquidity, partner payments, or future capital to sustain expansion.
Limited Recurring RevenueRevenue is concentrated in episodic collaboration payments rather than product sales or recurring royalties. This makes financial performance difficult to forecast and leaves future revenue dependent on clinical progress and partner decisions.
Clinical And Competitive RiskElevated placebo variability can reduce the reliability of atopic dermatitis trial outcomes, while competing STAT6 programs may narrow differentiation or market opportunity. Together, these factors increase uncertainty around pipeline value.
Kymera Therapeutics News
KYMR FAQ
What was Kymera Therapeutics, Inc.’s price range in the past 12 months?
Kymera Therapeutics, Inc. lowest stock price was $39.84 and its highest was $130.05 in the past 12 months.
What is Kymera Therapeutics, Inc.’s market cap?
Kymera Therapeutics, Inc.’s market cap is $9.96B.
When is Kymera Therapeutics, Inc.’s upcoming earnings report date?
Kymera Therapeutics, Inc.’s upcoming earnings report date is Oct 29, 2026 which is in 66 days.
How were Kymera Therapeutics, Inc.’s earnings last quarter?
Kymera Therapeutics, Inc. released its earnings results on Aug 05, 2026. The company reported -$0.62 earnings per share for the quarter, beating the consensus estimate of -$0.713 by $0.093.
Is Kymera Therapeutics, Inc. overvalued?
According to Wall Street analysts Kymera Therapeutics, Inc.’s price is currently Undervalued.
Does Kymera Therapeutics, Inc. pay dividends?
Kymera Therapeutics, Inc. does not currently pay dividends.
What is Kymera Therapeutics, Inc.’s EPS estimate?
Kymera Therapeutics, Inc.’s EPS estimate is -1.24.
How many shares outstanding does Kymera Therapeutics, Inc. have?
Kymera Therapeutics, Inc. has 83,150,620 shares outstanding.
What happened to Kymera Therapeutics, Inc.’s price movement after its last earnings report?
Kymera Therapeutics, Inc. reported an EPS of -$0.62 in its last earnings report, beating expectations of -$0.713. Following the earnings report the stock price went up 1.044%.
Which hedge fund is a major shareholder of Kymera Therapeutics, Inc.?
Currently, no hedge funds are holding shares in KYMR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kymera Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$131.33 (18.78% Upside)
$131.33 (18.78% Upside)
Blogger Sentiment
Bullish
KYMR Sentiment 60%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 383.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $174.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 1.8%
Last 30 Days ▼ 1.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
141.15%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
45.48%
Trailing 12-Months
Company Description
Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
KYMR Company Deck
KYMR Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial operational momentum: accelerated Phase 2b enrollment for KT-621, near-term KT-579 translational readout, partnership milestones that delivered $65M in Q2, and a strong balance sheet (~$1.5B) providing runway into 2029. At the same time, the company faces elevated near-term cash deployment (R&D up 22% QoQ), industry-wide challenges such as higher placebo responses in AD, a competitive STAT6 landscape, and limited near-term recurring revenue after recognition of deferred revenues. Overall, the positives — faster-than-expected enrollment, multiple upcoming data catalysts, partnership payments, and a solid cash position — meaningfully outweigh the risks and uncertainties discussed on the call.View all KYMR earnings summariesKYMR Stock 12 Month Forecast
Average Price Target
$131.33
▲(18.78% Upside)
Technical Analysis
Protagonist Therapeutics
―
―
Crinetics Pharmaceuticals
―
―
MoonLake Immunotherapeutics
―
Ownership Overview
11.97% Insiders
36.49% Mutual Funds
12.34% Other Institutional Investors
24.80% Public Companies and
Individual Investors